Video-on-Demand Library

This content is restricted to members of PSI. If you are already a member please login. To join PSI or to see all the benefits of membership click here.

05 May 2021

David Wright (AstraZeneca), James Bell (Elderbrook solutions GmbH), Michael O’Kelly (IQVIA), Daniel Bratton (GSK)

Incomplete datasets due to missing data is an issue that has been, and will be, around for a long time. At this meeting we will present the evolution of missing data approaches, looking at how they have been handled in the past, the current established missing data approaches and the impact of the new ICH E9 R1 addendum on the handling of missing data, focussing in particular on the treatment policy estimand.

David Wright (AstraZeneca) Aligning how subjects with missing data due to study discontinuation are handled in the primary analysis with the primary estimand. James Bell (Elderbrook solutions GmbH) The Practicalities of Treatment Policy Estimation Michael O’Kelly (IQVIA) Even a “treatment policy” estimand may have missing data: how can we take account of this? Daniel Bratton (GSK) Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Panel discussion (led by David Wright) and closing remarks.

Key Timings
03:38 
- Introduction & Welcome
05:20 - David Wright
45:08 - James Bell
1:27:05 - Michael O'Kelly
2:10:00 - Daniel Bratton
2:34:00 - Panel Q&A

Part of Collection(s)

Topic(s)

Upcoming Events

Latest Jobs